Predicting Outcomes of COVID-19 in Patients With Cancer
Findings from several studies can help clinicians predict outcomes of COVID-19 in patients with cancer.
All articles by Mark L. Fuerst
Advances Needed to Reduce Overdiagnosis of Breast Cancer
An estimated 15% of screen-detected breast cancer cases were overdiagnosed.
Patients With Cancer Should Receive COVID-19 Booster Shots
Researchers presented findings from CAPTURE, a prospective trial of COVID-19 vaccine or SARS-CoV-2-induced immunity in cancer patients.
Factors Tied to COVID-19 Severity, Recovery, and Death in Cancer Patients
Non-Caucasian patients had a greater risk of developing severe COVID-19, but Asian patients had a lower risk of death from COVID-19.
COVID-19 Prognosis Improved Over Time for Cancer Patients
Compared with patients who had COVID-19 during the second outbreak, patients diagnosed during the first outbreak had an increased risk of death at 14 days and at 3 months.
Most Solid Tumor Patients Have ‘Adequate’ Response to COVID-19 Vaccination, Regardless of Treatment
Responses in cancer patients were noninferior to responses in patients without cancer.
‘Practice-Changing’ Results With Sunitinib in Malignant Pheochromocytoma and Paraganglioma
The 12-month progression-free survival rate was 35.9% with sunitinib and 18.9% with placebo.
Ribociclib Improves Survival by More Than 1 Year in Advanced Breast Cancer
The overall survival benefit with ribociclib increased over time.
Novel Antibody-Drug Conjugate May Improve PFS in Advanced Breast Cancer
SYD985 may provide a new treatment option for patients with previously treated locally advanced or metastatic HER2-positive breast cancer.
Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma
Median OS was not reached for the T-VEC plus pembrolizumab arm and 49.2 months for the placebo plus pembrolizumab arm.
- Loading...
Loading...
Loading... 
Loading...